ReviewCurrent opinion in allergy and clinical immunology2025
Where eye meets body part 2: uniting allergy pathways in ocular and atopic disease - T cells take the lead.
Review in Current opinion in allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association Between Eosinophilic Esophagitis and Coded Ocular Diagnoses: A Retrospective Cohort Study.Life (Basel, Switzerland) · 2026Article
- Eosinophilic esophagitis is associated with increased risk of allergic conjunctivitis: a multicenter cohort study.Journal of ophthalmic inflammation and infection · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewThis review compares the T-cell-mediated pathways of atopic dermatitis and atopic keratoconjunctivitis (AKC), as well as allergic asthma and vernal conjunctivitis (VKC).These chronic, T cell-mediated conditions frequently coexist and are unified by Th2-driven inflammation, epithelial barrier dysfunction, and tissue remodeling. By comparing their epidemiology, pathogenesis, genetic contributors, and therapeutic approaches, this review examines how skin, airway, and ocular allergic pathways intersect and diverge. RECENT
findingsBarrier dysfunction and Th2-driven inflammation contribute to disease persistence across atopic dermatitis, AKC, allergic asthma, and VKC, with structural remodeling evident in chronic stages. In atopic dermatitis and allergic asthma, genetic studies implicate type 2 immune pathways, while in VKC, unfolded protein response genes are implicated; epigenetic changes, including DNA methylation and histone regulation, are emerging as shared contributors. Topical calcineurin inhibitors improve symptoms in both atopic dermatitis and AKC, though biologics like dupilumab may induce conjunctivitis in atopic dermatitis patients. Inhaled corticosteroids and anti-type 2 biologics remain mainstays for allergic asthma, while mast cell stabilizers and topical corticosteroids are used in VKC. New therapies, including JAK inhibitors and novel anti-inflammatory agents, offer additional options across these interconnected allergic diseases. SUMMARY: By highlighting immunologic convergence and divergence across these allergic conditions, this review underscores the importance of cross-specialty awareness and tailored treatments. Integrating ocular findings into broader allergy care may improve outcomes for patients with multicompartment involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.